• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

    8/11/22 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email

    Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.

    "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology."

    Dr. Barr has built his distinguished career at Merck Research Laboratories (MRL), a division of Merck & Co., Inc., a multinational pharmaceutical company, where he has served as Head of Global Clinical Development and Chief Medical Officer since April 2022. In this role, he oversees development programs for pipeline and in-line products in the Cardiovascular, Diabetes/Endocrine/Metabolism, Immunology, Neurology, Oncology, Psychiatry, Respiratory, and Vaccines/Infectious Diseases therapeutic areas. He is also the Chairperson of the Late Development Review Committee, the governance committee that oversees such pipeline. Dr. Barr has held numerous leadership positions within MRL since joining the company in 1995, including serving as Senior Vice President, Global Medical and Scientific Affairs from 2018 to 2022. Notably, he led the development of Merck's human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV. Prior to joining Merck, Dr. Barr pursued post-doctoral training at the University of Michigan and was on faculty at the University of Chicago. Dr. Barr earned his Doctor of Medicine degree from Jefferson Medical College of Thomas Jefferson University and completed an Internal Medicine residency and Cardiology Fellowship at Johns Hopkins.

    "Veracyte is a leader in providing high-value diagnostic tests that help physicians make more informed diagnostic and treatment decisions for their patients," said Dr. Barr. "I am excited to join Veracyte's board of directors and help guide the company as it executes on its bold, strategic global vision."

    About Veracyte

    Veracyte (NASDAQ:VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests, assays, biopharma business opportunities and immuno-oncology offerings. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "suggest," "may," "will" "prospective," "potential" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward-looking statement includes, among others, that the appointment of Eliav Barr, M.D., to our board of directors may help us achieve our ambition of improving outcomes for patients all over the world. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 28, 2022, and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

    Veracyte and the Veracyte logo are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005740/en/

    Get the next $VCYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Veracyte Inc.

      SC 13G - VERACYTE, INC. (0001384101) (Subject)

      11/12/24 9:30:49 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

      SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

      11/8/24 10:41:07 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

      SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

      10/2/24 2:12:30 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    See more
    • Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

      Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

      9/4/24 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

      Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a

      9/27/23 9:00:00 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

      Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo

      8/11/22 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP, Chief Accounting Officer Wygant Jonathan was granted 13,288 shares, increasing direct ownership by 36% to 49,763 units (SEC Form 4)

      4 - VERACYTE, INC. (0001384101) (Issuer)

      3/10/25 4:44:25 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Chief Scientific & Med Officer Febbo Phillip G. was granted 24,160 shares, increasing direct ownership by 29% to 106,700 units (SEC Form 4)

      4 - VERACYTE, INC. (0001384101) (Issuer)

      3/10/25 4:44:13 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Chief Financial Officer Chambers Rebecca was granted 30,200 shares, increasing direct ownership by 27% to 143,899 units (SEC Form 4)

      4 - VERACYTE, INC. (0001384101) (Issuer)

      3/10/25 4:44:02 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

        Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO, the annual meeting of the American Society of Clinical Oncology, being held May 30-June 3 in Chicago. Key findings shed new light on which patients with prostate or bladder cancer may be more likely to respond to specific therapies based on their tumors' molecular make-up. "These new findings underscore the power of our whole-transcriptome-based Decipher GRID, or Genomic Resource for Intelligent Discovery, research tool to help advance understanding of

      5/28/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte to Participate in Upcoming Investor Conferences

      Veracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics company whose visi

      5/20/25 5:00:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Announces First Quarter 2025 Financial Results

      Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a

      5/7/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Financials

    Live finance-specific insights

    See more
    • Veracyte Announces First Quarter 2025 Financial Results

      Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a

      5/7/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

      Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5r4msrbq. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/

      4/16/25 6:30:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

      Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact

      2/24/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Veracyte with a new price target

      Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

      3/20/25 7:42:48 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte downgraded by Goldman with a new price target

      Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously

      12/5/24 8:24:30 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on Veracyte with a new price target

      Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00

      11/15/24 8:25:09 AM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Veracyte Inc.

      10-Q - VERACYTE, INC. (0001384101) (Filer)

      5/8/25 8:06:25 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VERACYTE, INC. (0001384101) (Filer)

      5/7/25 4:07:43 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

      SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

      5/7/25 10:59:51 AM ET
      $VCYT
      Medical Specialities
      Health Care